For research use only. Not for therapeutic Use.
Regadenoson（Cat No.:I003110） is a medication that acts as an A2A adenosine receptor agonist and functions as a coronary vasodilator. It is frequently employed in pharmacologic stress testing, a diagnostic procedure used to evaluate the blood flow to the heart during exercise when a patient is unable to undergo physical stress. By stimulating the A2A adenosine receptors, regadenoson induces coronary artery dilation, increasing blood flow to the heart and mimicking the effects of exercise on the cardiovascular system.
| Catalog Number | I003110 |
| CAS Number | 313348-27-5 |
| Synonyms | (Z)-1-(6-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-2-yl)-N-methyl-1H-pyrazole-4-carbimidic acid |
| Molecular Formula | C15H18N8O5 |
| Purity | ≥95% |
| Target | Adenosine Receptor |
| Solubility | 10 mM in DMSO |
| Storage | 2-8°C |
| IUPAC Name | 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide |
| InChI | InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1 |
| InChIKey | LZPZPHGJDAGEJZ-AKAIJSEGSA-N |
| SMILES | CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N |
| Reference | </br>1:Regadenoson stress during low-level exercise: The EXERRT trial-does it move the needle? Mahmarian JJ.J Nucl Cardiol. 2017 May 15. doi: 10.1007/s12350-017-0873-4. [Epub ahead of print] No abstract available. PMID: 28508268 </br>2:Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging. Amer KA, Hurren JR, Edwin SB, Cohen G.Pharmacotherapy. 2017 May 5. doi: 10.1002/phar.1940. [Epub ahead of print] PMID: 28475259 </br>3:Accuracy of Rb-82 PET/CT MPI With Regadenoson Stress Including Three Year Clinical Outcomes Reporting PRESENT: PET/CT REgadenoson Stress Experience at the VA North Texas. Brophey M, Farukhi I, Castanon R, DeLaPena R, Bradshaw L, Banerjee S.J Nucl Med Technol. 2017 Apr 13. pii: jnmt.116.188938. doi: 10.2967/jnmt.116.188938. [Epub ahead of print] PMID: 28408703 </br>4:Common genetic polymorphisms of adenosine A2A receptor do not influence response to regadenoson. Berlacher M, Mastouri R, Philips S, Skaar TC, Kreutz RP.Pharmacogenomics. 2017 Apr;18(6):523-529. doi: 10.2217/pgs-2016-0178. Epub 2017 Mar 30. PMID: 28358597 </br>5:The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study. Jackson S, George RT, Lodge MA, Piotrowski A, Wahl RL, Gujar SK, Grossman SA.J Neurooncol. 2017 Mar 17. doi: 10.1007/s11060-017-2404-1. [Epub ahead of print] PMID: 28315063 </br>6:The EXERRT trial: /EXErcise to Regadenoson in Recovery Trial/: A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol. Thomas GS, Cullom SJ, Kitt TM, Feaheny KM, Ananthasubramaniam K, Gropler RJ, Jain D, Thompson RC.J Nucl Cardiol. 2017 Feb 21. doi: 10.1007/s12350-017-0813-3. [Epub ahead of print] PMID: 28224449 </br>7:The significance of post-stress decrease in left ventricular ejection fraction in patients undergoing regadenoson stress gated SPECT myocardial perfusion imaging. Gomez J, Golzar Y, Fughhi I, Olusanya A, Doukky R.J Nucl Cardiol. 2017 Feb 8. doi: 10.1007/s12350-017-0802-6. [Epub ahead of print] PMID: 28181156 </br>8:Regadenoson-induced hyperemia for absolute myocardial blood flow quantitation by <sup>13</sup>N-ammonia PET and detection of cardiac allograft vasculopathy. Packard RR, Maddahi J.J Nucl Cardiol. 2017 Jan 30. doi: 10.1007/s12350-016-0763-1. [Epub ahead of print] No abstract available. PMID: 28138814 </br>9:Noninvasive PET quantitative myocardial blood flow with regadenoson for assessing cardiac allograft vasculopathy in orthotopic heart transplantation patients. Pampaloni MH, Shrestha UM, Sciammarella M, Seo Y, Gullberg GT, Botvinick EH.J Nucl Cardiol. 2017 Jan 30. doi: 10.1007/s12350-016-0761-3. [Epub ahead of print] PMID: 28138813 </br>10:Regadenoson in Myocardial Perfusion Study – First Institutional Experiences in Bosnia and Herzegovina. Beslic N, Milardovic R, Sadija A, Ceric S, Raic Z.Acta Inform Med. 2016 Dec;24(6):405-408. doi: 10.5455/aim.2016.24.405-408. PMID: 28077904 Free PMC Article |
